An Early-Onset Advanced Rectal Cancer Patient With Increased KRAS Gene Copy Number Showed A Primary Resistance to Cetuximab in Combination With Chemotherapy: A Case Report

An Early-Onset Advanced Rectal Cancer Patient With Increased KRAS Gene Copy Number Showed A Primary Resistance to Cetuximab in Combination With Chemotherapy: A Case Report

Mutations in KRAS (codon 12/13), NRAS, BRAFV600E, and amplification of ERBB2 and MET account for 70–80% of anti-epidermal growth factor receptor (EGFR) monoclonal antibody primary resistance. However, the list of anti-EGFR monoclonal antibody primary resistance biomarkers is still incomplete. Herein...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tian Fang, Tingting Liang, Yizhuo Wang, Haitao Wu, Shuhan Liu, Linying Xie, Zhihao Zhang, Jiaying Liang, Cheng Yao, Yehui Tan, Chang Wang
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
KRAS
gene copy number
colorectal cancer
cetuximab
case report
anti-EGFR monoclonal antibody
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/641d4f9bb7764406b13f2d1505420918
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/641d4f9bb7764406b13f2d1505420918

Ejemplares similares